Pelargonium sidoides Pelargonium sidoides DC.
Also called: umckaloabo, Geranium sidifolium Thunb. (synonym), Pelargonium spectabile Sweet (synonym)
Pelargonium sidoides is a southern African plant whose root has a long traditional use for respiratory and digestive complaints. An EU herbal monograph accepts root extracts as traditional herbal medicines for common cold symptoms.
- Category
- Botanical
- Part used
- Root, as ethanolic liquid or dry extracts
- Strongest evidence
- B Some positive trials
- Native range
- Native to southern Africa (WCVP, the taxonomic index behind POWO: "S. Africa" — Cape Provinces, Eswatini, Free State, KwaZulu-Natal, Lesotho, Northern Provinces)
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2013 Cochrane review found 10 eligible double-blind RCTs of oral P. sidoides preparations (liquid or tablets) for acute respiratory infections and analyzed 8; 2 were of insufficient quality. It pooled at most 3 trials per condition. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Acute bronchitis in adults and children | B | A Cochrane review found three trials in adults (746 patients) and three in children (819) showing benefit for most outcomes with the liquid preparation but not tablets; evidence quality was low. [2] |
| Acute sinusitis and the common cold in adults | C | Single trials: one in 103 adults with sinusitis showed benefit at day 21; one in the common cold showed benefit at 10 days but not 5. Cochrane rated this evidence very low quality. [2] |
| Recovery and paracetamol use in children with bronchitis or tonsillopharyngitis | B | An individual-data meta-analysis of six placebo-controlled trials (523 children aged 6–10) found less paracetamol use and fewer children off school at treatment end; two authors were employees of Dr. Willmar Schwabe GmbH. [3] |
Main constituents: Polyphenols (e.g. catechin) and hydroxycoumarins (e.g. umckalin) as main constituents; also proanthocyanidins, flavan-3-ols, phenolic acids and gallic acid [1]; Highly substituted benzopyranones, prodelphinidins and coumarin sulfates [4]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Trials in the pediatric meta-analysis gave the extract for 6 days (tonsillopharyngitis) or 7 days (bronchitis). [3]
- EU monograph (2024), adolescents over 12 and adults: dry extract 20 mg three times daily (60 mg/day) or liquid extract 1.4 ml three times daily (4.2 ml/day); consult a doctor if symptoms last over 1 week. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No NIH LiverTox chapter on Pelargonium sidoides was found. The EU herbal monograph (2024) states that hepatotoxicity and hepatitis cases were reported with the medicinal …
Details and sources - Pregnancy and breastfeedingSafety during pregnancy and lactation has not been established …
1 statement in the profile.
Details and sources - Interactions with medicinesNone reported
Medicines in general: EU herbal monograph section 4.5: none reported.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (HMPC, traditional use, Revision 2 adopted 29 May 2024), adolescents over 12, adults and elderly: liquid extract (DER 1:8–10) 1.4 ml three times …
Details and sources
- Liver: the EU monograph warns that hepatotoxicity and hepatitis cases have been reported; use should stop immediately if signs of liver injury occur. [5]
- Hypersensitivity, including anaphylactic reactions, is listed as an undesirable effect of unknown frequency. [5]
- In the Cochrane review, adverse events were more common with P. sidoides than with control, but none were serious. [2]
- Pregnancy and breastfeeding: safety has not been established and use is not recommended. Use in children under 3 years is not recommended for the liquid extract. [5]
- Reported adverse reactions include gastrointestinal upset and allergic reactions. [1]
Interactions
| With | What happens |
|---|---|
| Medicines in general | The EU monograph lists no reported interactions. [5] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
Regulatory status
- EU: European Union herbal monograph (HMPC, traditional use; Revision 2 adopted 29 May 2024) for P. sidoides and/or P. reniforme root; indication: traditional herbal medicinal product for the symptomatic treatment of common cold, based exclusively on long-standing use. [5]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; manufacturers and distributors have initial responsibility for their safety. [6]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming Pelargonium sidoides was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No NIH LiverTox chapter on Pelargonium sidoides was found. The EU herbal monograph (2024) states that hepatotoxicity and hepatitis cases were reported with the medicinal product and that use should stop immediately if signs of hepatotoxicity occur. [P5]
Interactions with medicines
- Medicines in general: EU herbal monograph section 4.5: none reported. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each dietary-ingredient component (21 CFR 111.75(a)(1)(i)) — Required by the US dietary supplement cGMP rule for any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P6]
- Chromatographic fingerprint (HPLC, LC-MS or TLC) — These methods are summarized in the literature for standardization of P. sidoides root preparations. [P7]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P8]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (HMPC, traditional use, Revision 2 adopted 29 May 2024), adolescents over 12, adults and elderly: liquid extract (DER 1:8–10) 1.4 ml three times daily (4.2 ml/day), or dry extract 20 mg three times daily (60 mg/day). Children 6–12 and 3–5 years have lower stated doses. If symptoms persist longer than 1 week, a doctor should be consulted. [P5]
Pregnancy and breastfeeding
- Safety during pregnancy and lactation has not been established; in the absence of sufficient data, use during pregnancy and lactation is not recommended (EU herbal monograph, 2024). [P5]
Sources for this profile
- Memorial Sloan Kettering Cancer Center. About Herbs: Pelargonium sidoides (last updated July 24, 2023), 2023-07-24. mskcc.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Agents classified by the IARC Monographs, Volumes 1–142 (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Pelargonium sidoides DC. and/or Pelargonium reniforme Curt., radix, Revision 2 (EMA/HMPC/648100/2022; adopted 29 May 2024), 2024-05-29. ema.europa.eu
- eCFR. 21 CFR 111.75 (Title 21 up to date as of 10/27/2026), 2026-10-27. ecfr.gov
- Honchar O, et al. Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review. Phytomedicine 2026;153:157880 (PMID 41653615), 2026-04. pubmed.ncbi.nlm.nih.gov
- GBIF species API: IUCN Red List category for Pelargonium sidoides, 2026-10-29. api.gbif.org
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Pelargonium sidoides (last updated July 24, 2023), 2023-07-24. mskcc.org
- Timmer A, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013;(10):CD006323 (PMID 24146345), 2013-10-22. pubmed.ncbi.nlm.nih.gov
- Seifert G, et al. Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC Pediatr 2019;19:119 (PMID 31014293), 2019-04-23. pubmed.ncbi.nlm.nih.gov
- Honchar O, et al. Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review. Phytomedicine 2026;153:157880 (PMID 41653615), 2026-04. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Pelargonium sidoides DC. and/or Pelargonium reniforme Curt., radix, Revision 2 (EMA/HMPC/648100/2022; adopted 29 May 2024), 2024-05-29. ema.europa.eu
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- WCVP (World Checklist of Vascular Plants, the taxonomic index to POWO), Darwin Core archive via GBIF species API: Pelargonium sidoides DC., accepted, native range "S. Africa" (retrieved 2026-10-29); synonyms and botanical-country distribution from WCVP. POWO page: https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:377008-1, 2026-10-29. api.gbif.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.